JPX-1188

**JPX-1188** is an investigational **small-molecule targeted protein degrader** developed by **Janpix** and later associated with **Centessa Pharmaceuticals** following Centessa's acquisition of Janpix. Preclinical disclosures describe it as a **covalent monovalent dual degrader of STAT3 and STAT5**, producing rapid, potent, and selective degradation of these transcription factors in leukemic cells, with downstream suppression of JAK/STAT signaling and induction of apoptotic cell death. Reported development focus was in hematologic malignancies such as **acute myeloid leukemia** and **T-cell prolymphocytic leukemia**, but publicly available pipeline sources indicate that the program was **terminated/discontinued at the preclinical stage**.